xCures Announces Advisory Appointments

xCures announced today that it has named David Hartford and Elizabeth Hutt Pollard as senior advisors.

“We are extremely pleased to be able to draw on David and Elizabeth’s knowledge and experience as xCures is changing how advanced cancer patients are served in their treatment,” said Mika Newton, CEO of xCures. “David’s expertise in investing at the intersection of technology and life sciences will bring us a valuable perspective on how we interact with the biopharmaceutical companies and the investor community. Similarly, Elizabeth’s work in the business of advancing paths to treatment and medical research provides us yet more understanding to further our work in Perpetual Trials and Virtual Tumor Boards.”

About David Hartford

David Hartford was a founding partner of Calibrium AG (formerly known as Aeris Capital) and now is senior advisor to the firm. Calibrium manages funds for the family office of a successful European entrepreneur, as well as for his foundation, one of the largest in Germany. In addition to his role at Calibrium, David serves on a number of boards of directors in support of early-stage technology companies.

David has more 40 years of experience in the U.S. and Europe as a private equity investor, venture capitalist and entrepreneur. During his career, he has also undertaken direct C-suite roles and been a practicing securities attorney. David began his career as a systems specialist with Rockwell International.

David received his BS from the University of Pittsburgh, his JD from the University of Pennsylvania, and completed the Advanced Executive Program “Competing in a Global Environment” at The Anderson School at UCLA.

About Elizabeth Hutt Pollard

Elizabeth Hutt Pollard, is Executive Chair of Applied Silver, Inc. a privately held company addressing soft surface infection prevention in the health, athletic and consumer markets. She currently serves as a strategic advisor to several early-stage life science companies and holds leadership positions in YPO, the premier leadership organization of chief executives in the world.

Prior to joining Applied Silver, Elizabeth was CEO of NuGEN Technologies, a global leader in genomic sample preparation products enabling scientists and clinicians to discover genetic signatures and predict disease risk and drug response, potentially shortening the path to treatment. Elizabeth has also held US and International management roles with Tripos, Affymetrix, and Life Technologies, during significant growth phases of these life science businesses

Elizabeth spent three years as a research associate at the University of Michigan in the Departments of Hematology/Oncology, where she made the decision to have a broader impact on medical research by transitioning into a career within the commercial biotechnology sector. She holds a BA in Chemistry from Michigan State University and an M.S. in Administration from Central Michigan University.

Integrating Clinical Research And Care In A Perpetual Trial

With attention focused on the difficulties associated with traditional oncologic clinical trials, xCures’ Perpetual Trial and the potential for a Real World Data-based learning ecosystem has gained attention. Recently, Diagnostic World News interviewed xCures CEO Mika Newton about Perpetual Trials, AI, and the future of accelerating treatment and knowledge in the development of cancer treatments. To see more, go to Diagnostic World News.

Oncology Expert Keith T. Flaherty, MD Named Chairman of xCures Scientific Advisory Board

Keith T. Flaherty, MD, has joined the xCures Scientific Advisory Board as Chairman. The Scientific Advisory Board supports the work of xCures’ Virtual Tumor Boards in running patient-centered “Perpetual Trials” for oncology. xCures currently runs XCELSIOR, a Perpetual Trial integrating real-world data and patient-reported outcomes with an AI-enhanced Virtual Tumor Board. By implementing this precision oncology approach to the treatment of all cancer patients, on all therapies, all the time, xCures aims to develop deep insight into rapid improvements in the treatment of cancer patients.

“Keith Flaherty brings unparalleled experience in targeted therapy and will be an invaluable addition to the essential activities of our Scientific Advisory Board as more and more we bring real world evidence and patient-centered approaches to research to bear for patients in their fights against cancer,” said Mika Newton, CEO of xCures.

The xCures Scientific Advisory Board’s efforts include developing a portfolio of leading drugs for each of the major molecular mechanisms/pathways driving cancer and providing these options as input for xCure’s Virtual Tumor Boards to consider when formulating treatment options for cancer patients and their doctors. In conjunction with the Advisory Board, xCures works to establish relationships with the manufacturers of those drugs to make them part of the company’s compassionate access compendium. This makes these options more readily available to patients and their physicians. The Scientific Advisory Board will also consider outside entities submitting their hypotheses or therapies as treatment options for considerations by the Virtual Tumor Boards.

“Defeating cancer demands new approaches that both capture and disseminate treatment information broadly and efficiently,” said Dr. Flaherty. “These approaches must take into account the fact that there are far too many rational treatments to try and that traditional trials are far too expensive. I am thrilled to work with xCures as they further develop a revolutionary platform that can rapidly evaluate new therapeutic options at a fraction of the time and cost of traditional trials.”

Keith Flaherty, MD, is Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center, where he was named as the Richard Saltonstall Endowed Chair in Oncology.

Press Release

xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-Mutant Gliomas

LOS ALTOS, Calif., March 12, 2019 /PRNewswire/ — xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled “ONC018: Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas” that was recently accepted by the U.S. Food and Drug Administration (FDA).

The H3 K27M mutation has been identified as an important prognostic indicator in aggressive midline gliomas that involve specific parts of the brain, including the thalamus, pons, or spinal cord. In 2016, the World Health Organization categorized any midline brain tumor that contains the H3 K27M mutation as the highest grade (IV) because the mutation confers such a poor prognosis. Beyond palliative radiation, no medical therapy has been shown to provide clinical benefit for patients with this mutation in their tumor. Pediatric patients are particularly impacted by this mutation, especially those with DIPG where 70-80% of the patients have the mutation.

Press Release